The FDA approved AbbVie’s next-generation dopamine therapy for Parkinson’s disease, tavapadon, which will be marketed as Juvmo. The dopamine agonist is positioned as a successor to existing symptomatic drugs, with the company expecting fewer side effects while retaining efficacy for motor symptoms. For biotech and pharma stakeholders, the approval underscores continued interest in improving tolerability for chronic CNS therapies, where long-term adherence and adverse-event management can be as important as symptom control. The label also adds another competitive entry point as Parkinson’s programs increasingly differentiate on safety profiles and dosing convenience.